Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.
Afrezza is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results